A year ago we published an effective treatment for West Nile virus encephalitis but most people haven’t heard about it. Articles about WNV still claim there are no known treatments.
Since we use already FDA-approved medications, and we’ve published our results in a peer-reviewed medical journal, the FDA has no problem with it.
Our clinical record since 2003 involves 15 patients, with 12 unexpectedly rapid recoveries and 3 deaths. Clinically, none of these 15 people were expected by their physicians to recover so quickly, if at all.
The 3 deaths were as follows: 1 woman with chronic leukemia (so we limit our approach to immunocompetent patients, not immunosuppressed ones), and 2 elderly women who had been in coma for a month already (so we try to get to patients as early as possible. In fact, the granddaughter of one of these women established a memorial fund to try to increase public awareness of our treatment approach).
We published our first 8 cases last summer. They’re described in Table 2 of:
Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem. 2004;4(13):1433-54. PMID: 15379656 [PubMed - indexed for MEDLINE]
Anybody who thinks they have West Nile fever and who wants to enroll in our free trial just needs to click on the “West Nile trial†link at our website, http://www.genomed.com. They can do this any time of day or night. They just need to print out the trial documents and show them to their doctor to get started on the trial which requires a doctor’s prescription. Their doctor acts as a kind of super-strict “Institutional Review Board (IRB)†to decide whether the trial is in the patient’s best interest.
Although not yet endorsed by the CDC, our approach has piqued the interest of the biodefense community, because it may work for most viruses, not just West Nile virus.
Our work has attracted the favorable interest of the White House Office of Science, Technology, and Policy (OSTP), the Department of Homeland Security, and the Chief of Virology at the NIH. Our approach was specifically included in BioShield II, the latest version of the biodefense bill introduced into the U.S. Senate this past April. If the bill passes, the CDC will have 6 months to report back to Congress on our approach, so the CDC will need to collaborate with us eventually, although they have chosen not to for the past 3 summers.
Our treatment approach is described in Section 2151.
Although the bill won’t get voted on until next summer, that doesn’t change the fact that we appear to have a safe, inexpensive, universally available, and effective cure for West Nile virus right now. Families of patients with WNV encephalitis this summer may appreciate hearing about it now, since treatment efficacy seems to depend on how quickly after infection the treatment is begun.
[...] The trouble is Red Tide is a mostly natural phenomenon. Like living with hurricanes, mosquitoes, and tourists, there is nothing we can do about it except hold our breath and wait. I call it paying the rent. Learn more about Red Tide. [...]
Dave Moskowitz MD
4 years ago
A year ago we published an effective treatment for West Nile virus encephalitis but most people haven’t heard about it. Articles about WNV still claim there are no known treatments.
Since we use already FDA-approved medications, and we’ve published our results in a peer-reviewed medical journal, the FDA has no problem with it.
Our clinical record since 2003 involves 15 patients, with 12 unexpectedly rapid recoveries and 3 deaths. Clinically, none of these 15 people were expected by their physicians to recover so quickly, if at all.
The 3 deaths were as follows: 1 woman with chronic leukemia (so we limit our approach to immunocompetent patients, not immunosuppressed ones), and 2 elderly women who had been in coma for a month already (so we try to get to patients as early as possible. In fact, the granddaughter of one of these women established a memorial fund to try to increase public awareness of our treatment approach).
We published our first 8 cases last summer. They’re described in Table 2 of:
Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem. 2004;4(13):1433-54. PMID: 15379656 [PubMed - indexed for MEDLINE]
The PDF file for this paper can be downloaded from:
http://www.genomed.com/pdf/ACE_vertebrate_pathophysiology.pdf
Anybody who thinks they have West Nile fever and who wants to enroll in our free trial just needs to click on the “West Nile trial†link at our website, http://www.genomed.com. They can do this any time of day or night. They just need to print out the trial documents and show them to their doctor to get started on the trial which requires a doctor’s prescription. Their doctor acts as a kind of super-strict “Institutional Review Board (IRB)†to decide whether the trial is in the patient’s best interest.
Although not yet endorsed by the CDC, our approach has piqued the interest of the biodefense community, because it may work for most viruses, not just West Nile virus.
Our work has attracted the favorable interest of the White House Office of Science, Technology, and Policy (OSTP), the Department of Homeland Security, and the Chief of Virology at the NIH. Our approach was specifically included in BioShield II, the latest version of the biodefense bill introduced into the U.S. Senate this past April. If the bill passes, the CDC will have 6 months to report back to Congress on our approach, so the CDC will need to collaborate with us eventually, although they have chosen not to for the past 3 summers.
BioShield II is now called Senate bill S. 975, and can be viewed at:
http://www.govtrack.us/congress/billtext.xpd?bill=s109-975
Our treatment approach is described in Section 2151.
Although the bill won’t get voted on until next summer, that doesn’t change the fact that we appear to have a safe, inexpensive, universally available, and effective cure for West Nile virus right now. Families of patients with WNV encephalitis this summer may appreciate hearing about it now, since treatment efficacy seems to depend on how quickly after infection the treatment is begun.
Yours sincerely,
David W. Moskowitz MD FACP
Chief medical officer & CEO
GenoMed, Inc.
http://www.genomed.com
St. Louis, MO
tel. 314-983-9933
dwmoskowitz@genomed.com
Sticks of Fire: a Tampa blog » rent is due
4 years ago
[...] The trouble is Red Tide is a mostly natural phenomenon. Like living with hurricanes, mosquitoes, and tourists, there is nothing we can do about it except hold our breath and wait. I call it paying the rent. Learn more about Red Tide. [...]